Article Text
Abstract
Background/Aim Gyrate atrophy of the choroid and retina (GACR) is an extremely rare autosomal recessive inherited disorder characterised by progressive vision loss. To identify the disease-causing gene in a consanguineous Chinese pedigree with GACR, we aimed to accurately diagnose patients with GACR through a combination of next-generation sequencing (NGS) genetic diagnosis, clinical imaging and amino acid metabolic analysis.
Methods A consanguineous Chinese pedigree with GACR, including two patients, was recruited and a comprehensive ophthalmological evaluation was performed. DNA was extracted from a proband and her family members, and the sample from the proband was analysed using targeted NGS. Variants detected by NGS were confirmed by Sanger sequencing and subjected to segregation analysis. Tandem mass spectrometry (MS/MS) was subsequently performed for metabolic assessment.
Results We identified a novel, deleterious, homologous ornithine aminotransferase (OAT) variant, c.G248A: p.S83N, which contributes to the progression of GACR in patients. Our results showed that the p.S83N autosomal recessive variant of OAT is most likely pathogenic, with changes in protein stability drastically decreasing functionality. MS/MS verified that ornithine levels in patients were significantly elevated.
Conclusions Recruitment of a third-degree first cousin consanguineous marriage family with GACR allowed us to identify a novel pathogenic OAT variant in the Chinese population, broadening the mutation spectrum. Our findings reported the diagnostic value of a combination of NGS, retinal imaging and metabolic analysis of consanguineous marriage pedigrees in low-income/middle-income and low-incidence countries, including China, and may help to guide accurate diagnosis and treatment of this disease.
- genetics
- vision
- diagnostic tests/investigation
- biochemistry
Statistics from Altmetric.com
Footnotes
JH, JF and SF are Co-first authors.
Contributors JF, RC and HL: idea, project design and concept of the paper. JiF, JF, JC, SF and LY: DNA extraction, RNA extraction, PCR, RT-PCR, bioinformatic analysis, Sanger sequencing and data analysis. RC and YL: NGS analysis. JH, LL, HL, KN and CD: clinical patient recruitment and clinical assessment. JH: metabolic disorder analysis. JF and SF: manuscript writing. JF, LL and HL: manuscript revision.
Funding This work was supported in part by the National Natural Science Foundation of China (30371493, 31701087, 81172049 and 81672887), and the Joint Research Foundation of Luzhou City and Southwest Medical University (2018).
Competing interests None declared.
Patient consent Obtained.
Ethics approval The study protocol was approved by the ethical committees of Southwest Medical University/Sichuan University (Luzhou, China), and all procedures adhered to the tenets of the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.